Research programme: leptin-based immunotherapeutics - Imperial College Innovations

Drug Profile

Research programme: leptin-based immunotherapeutics - Imperial College Innovations

Latest Information Update: 03 Sep 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Developer Imperial Innovations; Nonindustrial source
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Immunological disorders; Immunosuppression

Most Recent Events

  • 29 Sep 1999 New profile
  • 29 Sep 1999 Technology available for licensing from Imperial College Innovations (e-mail:
  • 29 Sep 1999 Preclinical development for Immunological disorders in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top